According to filings with the U.S. Securities and Exchange Commission, Alveus Therapeutics is raising up to $110,724,980.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Alveus Therapeutics
Alveus Therapeutics is a company dedicated to redefining weight management by building a differentiated therapeutic portfolio aimed at delivering sustainable weight loss with superior tolerability. The company focuses on addressing the critical challenge of weight maintenance that limits current treatments, utilizing human genetic data, deep biological and clinical expertise, and rigorous program selection. Their approach targets well-established human validation and clear mechanistic rationales to develop first- or best-in-class molecules for the evolving obesity treatment landscape. Alveus Therapeutics’ development pipeline is concentrated on next-generation metabolic therapies, with its lead asset, ALV-100, currently in Phase 2, and a preclinical amylin pipeline featuring best-in-class peptides, oral small molecules, and other novel formats. The company recently launched with $160 million in Series A financing to advance these next-generation therapies for obesity and metabolic diseases.

To learn more about Alveus Therapeutics, visit https://alveustx.com/
Alveus Therapeutics Linkedin Page: https://www.linkedin.com/company/alveus-therapeutics/

Contact:
Raj Kannan, Chief Executive Officer
215-419-7830

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.